Showing results (121-130 of 6,842) with videos related to

Sort By:
Pageof 685
Alzheimer Disease and Associated Disorders|July 2, 2009
Lethality of Alzheimer disease and its impact on nursing home placementHenry Michael Arrighi, Peter J Neumann, Ivan M Lieberburg, et al.
Pharmacoeconomics|April 6, 2004
How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?Bruce R Schackman, Heather Taffet Gold, Patricia W Stone, et al.
Health Policy (Amsterdam, Netherlands)|February 20, 2013
What can we learn from the U.S. expanded end-stage renal disease bundle?James D Chambers, Daniel E Weiner, Sarah K Bliss, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 12, 2013
Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disordersPei-Jung Lin, Howard M Fillit, Joshua T Cohen, et al.
Journal of Managed Care & Specialty Pharmacy|November 28, 2018
Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage PoliciesJames D Chambers, Elle F Pope, Colby L Wilkinson, et al.
Health Affairs (Project Hope)|October 8, 2014
Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugsJames D Chambers, Teja Thorat, Junhee Pyo, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 12, 2025
Cost-Effectiveness of the 15 Drugs Selected for Initial Price Applicability Year 2027 by Centers for Medicare and Medicaid Services Drug Price Negotiation ProgramFeng Xie, Ting Zhou, Yue Ma, et al.
Women'S Health Issues : Official Publication of the Jacobs Institute of Women'S Health|July 4, 2016
Educational Attainment and Gestational Weight Gain among U.S. MothersAlison K Cohen, Chandni Kazi, Irene Headen, et al.
Managed Care Interface|August 9, 2006
The economic burden of intracerebral hemorrhage: evidence from managed careMason W Russell, Luke Boulanger, Ashish V Joshi, et al.
Pageof 685